Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Die Europäische Arzneimittelagentur (EMA) hat PolTREG offiziell die Berechtigung erteilt, einen Antrag auf Marktzulassung für das Zellpräparat PolTREG-T1D in der Europäischen Union zu stellen. ...
-
L’Agence européenne des médicaments (EMA) a officiellement autorisé PolTREG à déposer une demande d’autorisation de mise sur le marché dans l’Union européenne pour la préparation cellulaire...
-
The European Medicines Agency (EMA) has officially qualified PolTREG to submit an application for marketing authorization in the European Union for the PolTREG-T1D cell preparation. GDAŃSK, Poland,...
-
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies Dr. Adrian Bot, a renowned biopharmaceutical founder and...
-
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007 PTG-007, an autologous cell therapy will be administered to 150 high-risk children aged 3–18,...
-
PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial FDA agreed that PolTREG’s clinical data in Stage 3...
-
Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions Distinguished experts Dr. Jay Skyler, Dr. Desmond Schatz, and Dr....
-
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy PolTREG established Immuthera (https://immuthera.bio/) in Delaware to expand its...
-
Positive EMA Opinion on Pediatric Investigation Plan for PolTREG’s Treg Therapy in Type 1 Diabetes The Paediatric Committee (PDCO) of the European Medicines Agency issues positive...
-
Treating diabetes patients earlier with PTG-007 could provide functional cureRecruitment will go ahead after European Medicines Agency approvalCompany has 12 years’ worth of safety...